Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22355133 | 1.00 | CFD (0.46) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL26136945 | 1.00 | CFD (0.46) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL29544847 | 0.91 | CFD (0.56) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL29545064 | 0.91 | CFD (0.56) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL17023818 | 0.91 | CFD (0.56) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL20321739 | 0.91 | CFD (0.47) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL17023850 | 0.91 | CFD (0.56) | CFDPOLBCYP3A4CYP2C19CYP1A2 | |
| SCHEMBL18572756 | 0.90 | MEN1 (0.51) | CFDPOLBMEN1KMT2AHDAC8 | |
| SCHEMBL22355132 | 0.90 | MEN1 (0.51) | CFDPOLBMEN1KMT2AHDAC8 | |
| SCHEMBL25929637 | 0.90 | MEN1 (0.51) | CFDPOLBMEN1KMT2AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210122733-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-20210115034-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| US-10919884-B2 | Amide compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10906887-B2 | Amino compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10662175-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180179186-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180179185-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122733-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2930/4885CYP3A4 3594/4885 |
| US-20180186782-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2599/4885CYP3A4 3071/4885 |
| US-20200071301-A1 | Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CFD 1/4885POLB 4302/4885CYP3A4 81/4885 |
| US-10919884-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 2599/4885CYP3A4 3071/4885 |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 2594/4885CYP3A4 3333/4885 |
| US-20180179186-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 3332/4885CYP3A4 617/4885 |
| US-11649229-B2 | Amide compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 2599/4885CYP3A4 3071/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CFD 1/4885POLB 3304/4885CYP3A4 57/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 3304/4885CYP3A4 57/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 3304/4885CYP3A4 57/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2864/4885CYP3A4 337/4885 |
| US-20180179185-A1 | AMINO COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2930/4885CYP3A4 3594/4885 |
| US-11649223-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 2930/4885CYP3A4 3594/4885 |
| US-10906887-B2 | Amino compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 2930/4885CYP3A4 3594/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2594/4885CYP3A4 3333/4885 |
| US-11084800-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | CFD 1/4885POLB 3304/4885CYP3A4 57/4885 |
| US-20210115034-A1 | AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | CFD 1/4885POLB 2599/4885CYP3A4 3071/4885 |
| US-10662175-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | CFD 1/4885POLB 3332/4885CYP3A4 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.